Source-grounded facts extracted from bioAffinity Technologies, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
bioAffinity Technologies, Inc. reported first quarter ended March 31, 2026 results: revenue $1.4 million.
“Lung testing revenue increased approximately 114% to $361,000 , compared to $169,000 in the first quarter of 2025. ● Total consolidated revenue decreased approximately 27% to $1.4 million , compared to $1.9 million for the first quarter of 2025, resulting from the discontinuation of certain unprofitable pathology services in March 2025 to focus on higher margin”
bioAffinity Technologies, Inc.: Increased authorized shares of Common Stock from 100,000,000 to 350,000,000 and designated Series B Convertible Preferred Stock (effective 2025-08-13).
“On August 13, 2025, the Company filed a Certificate of Amendment to the Company’s Certificate of Incorporation (the “Certificate of Amendment”) to increase the number of authorized shares of the Company’s Common Stock from 100,000,000 to 350,000,000.”
bioAffinity Technologies, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2)).
“ies will be scheduled for delisting from The Nasdaq Capital Market and will be suspended at the opening of business on August 18, 2025. In addition, as of the date hereof, the Company has not regained compliance with the Continued Listing Equity Requirement. As a result and pursuant to Listing Rule 5810(d)(2), this deficiency now serves as an additional basis for delisting of the Company’s securities. The Company intends to submit an appeal to Nasdaq on August 14, 2025, which will stay the delisting and suspension of the Company’s securities pending the decision of the Panel. Hearings are typi”
bioAffinity Technologies, Inc. received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)(1)).
“ies will be scheduled for delisting from The Nasdaq Capital Market and will be suspended at the opening of business on August 18, 2025. In addition, as of the date hereof, the Company has not regained compliance with the Continued Listing Equity Requirement. As a result and pursuant to Listing Rule 5810(d)(2), this deficiency now serves as an additional basis for delisting of the Company’s securities. The Company intends to submit an appeal to Nasdaq on August 14, 2025, which will stay the delisting and suspension of the Company’s securities pending the decision of the Panel. Hearings are typi”
bioAffinity Technologies, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).
“May 27, 2025, bioAffinity Technologies, Inc. (the “Company”) received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company was not in compliance with Nasdaq Listing Rule 5550(b)(1) (the “Rule”) because the stockholders’ equity of the Company of $1,439,404 as of March 31, 2025, as reported in the Company’s Quarterly Report on Form 10-Q filed with the SEC on May 15, 2025, was below the minimum requirement of $2,500,000. As of the date of this Current Report on Form 8-K, the Company does not have a market value of listed secu”
Stuart Diamond departed as Director at bioAffinity Technologies, Inc..
“On April 12, 2025, Stuart Diamond, a member of the board of directors (the “Board”) of bioAffinity Technologies, Inc., a Delaware corporation (the “Company”), notified the Company of his decision not to stand for re-election at the Company’s 2025 annual meeting of stockholders (the “2025 Annual Meeting”).”
bioAffinity Technologies, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
“February 7, 2025, bioAffinity Technologies, Inc. (the “Company”) received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that for the preceding 30 consecutive business days (December 23, 2024 through February 6, 2025), the Company’s common stock did not maintain a minimum closing bid price of $1.00 (“Minimum Bid Price Requirement”) per share as required by Nasdaq Listing Rule 5550(a)(2). The notice has no immediate effect on the listing or trading of the Company’s common stock and the common stock will continue to trade”
bioAffinity Technologies, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
“February 7, 2025, bioAffinity Technologies, Inc. (the “Company”) received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that for the preceding 3”
bioAffinity Technologies, Inc.: Amended quorum requirement to 34% of outstanding shares entitled to vote (effective 2024-10-17).
“On October 17, 2024, the Board amended the Company’s Amended and Restated By-Laws, effective October 17, 2024, in order to amend the quorum requirement of Article II, Section 2.07 of the Amended and Restated By-Laws, such that thirty-four percent (34%) of the outstanding shares of stock of the Company entitled to vote at the meeting, present in person or represented by proxy, shall constitute a quorum for the transaction of business at all meetings of the stockholders.”
J. Michael Edwards was appointed as Chief Financial Officer at bioAffinity Technologies, Inc..
“On October 4, 2024, the Board of Directors (the “Board”) of bioAffinity technologies, Inc. (the “Company”) appointed J. Michael Edwards, who has served as the Company’s Interim Chief Financial Officer, as a consultant, since September 2024, to serve as Chief Financial Officer of the Company, effective November 5, 2024.”
Michael Edwards was appointed as Interim Chief Financial Officer and Principal Accounting Officer at bioAffinity Technologies, Inc..
“the Board of Directors of the Company appointed, effective as of September 16, 2024, Michael Edwards, age 57, to serve as the Company’s Interim Chief Financial Officer and Principal Accounting Officer.”
Michael Dougherty resigned as Chief Financial Officer and Principal Accounting Officer at bioAffinity Technologies, Inc..
“Michael Dougherty notified bioAffinity Technologies, Inc. (the "Company") of his decision to resign from his position as the Company’s Chief Financial Officer and Principal Accounting Officer to pursue other opportunities.”
bioAffinity Technologies, Inc. reported the three months ended March 31, 2024 results: revenue $2.4 million, net income $2.1 million, EPS $0.21 per share. Guidance raised.
“First Quarter Financial Results Revenue for the first quarter of 2024 was $2.4 million, compared with $921 revenue for the prior-year period. The majority of the year-over-year increase is through the acquisition of Precision Pathology Laboratory Services. Revenue is primarily generated from patient service fees, including billing for CyPath ® Lung tests, with additional revenues generated from histology service fees and medical director fees. Research and development expenses were $394,000 for the first quarter of 2024, compared with $370,000 for the comparable period in 2023. The increase was primarily due to higher compensation costs for additional research personnel and higher R&D laboratory supply costs. Clinical development expenses were $49,000 for the first quarter of 2024, compared with $20,000 for the first quarter of 2023. The increase was primarily due to an increase in compensation costs and benefits from the addition of new clinical development personnel. Selling, general”
bioAffinity Technologies, Inc. reported the three and 12 months ended December 31, 2023 results: revenue $2.5 million, net income $7.9 million, EPS $0.91 per share.
“expanding our market to fulfill the promise of early cancer detection and treatment.” Fourth Quarter Financial Results Revenue for the fourth quarter of 2023 was approximately $2.2 million, up from no revenue for the prior-year period. Revenue was derived from sales and services of the Company’s commercial laboratory, Precision Pathology Laboratory Services,”
bioAffinity Technologies, Inc. entered into Securities Purchase Agreement with four institutional investors valued at aggregate gross proceeds of approximately $2.5 million (effective 2024-03-06).
“On March 6, 2024, bioAffinity Technologies, Inc. (the "Company") entered into a Securities Purchase Agreement (the "Purchase Agreement") with four institutional investors (the "Purchasers"), pursuant to which the Company will issue to the Purchasers, (i) in a registered direct offering, 1,600,000 shares of the Company’s common stock (the "Shares"), par value $0.007 per share ("Common Stock") and (ii) in a concurrent private placement, warrants to purchase an aggregate of 1,600,000 shares of Common Stock (the "Common Warrants") with an exercise price of $1.64.”
Mohsin Y. Meghji resigned as Director at bioAffinity Technologies, Inc..
“On December 1, 2023 , Mohsin Y. Meghji resigned from the Board of Directors, effective immediately, for personal reasons, and not due to any disagreement with the Company or its operations, policies or practices.”
Jamie Platt was appointed as Director at bioAffinity Technologies, Inc..
“On December 1, 2023, the Board of Directors (the “Board”) of bioAffinity Technologies, Inc. (the “Company”) appointed Jamie Platt, Ph.D., to serve as a director of the Company.”
bioAffinity Technologies, Inc. reported financial results for quarter ended September 30, 2023.
“On November 14, 2023, bioAffinity Technologies, Inc., a Delaware corporation (the "Registrant"), issued a press release that included financial information for its quarter ended September 30, 2023.”
bioAffinity Technologies, Inc. reported three and nine months ended Sept. 30, 2023 results: revenue $298,484, EPS $0.26 per share. Guidance reaffirmed.
“with larger medical systems, we anticipate substantial revenue growth for CyPath ® Lung.” Third Quarter Financial Results Revenue for the third quarter of 2023 increased to $298,484, up from $1,150 in the prior-year period. Prior to the Sept. 18, 2023, acquisition of PPLS, bioAffinity Technologies’ revenue was generated from royalties from sales of CyPath ®”
bioAffinity Technologies, Inc. completed an acquisition involving Village Oaks Pathology Services, P.A. d/b/a Precision Pathology Services for $3,500,000 (closed 2023-09-18).
“now owned by PPLS, and related services business, and assumed certain liabilities and obligations. Pursuant to the terms of the Asset Purchase Agreement, Village Oaks received $3,500,000 in consideration for the Laboratory Assets purchased by PPLS, of which $1,000,000 was paid by the issuance of 564,972 shares of the Company’s restricted common stock to the Joyce”
bioAffinity Technologies, Inc. amended Warrant Amendment with Mr. Girgenti, the Cranye Girgenti Testamentary Trust, Gary Rubin, The Harvey Sandler Revocable Trust, Ms. Zannes and Dr. Joyce (effective 2023-09-17).
“On September 17, 2023, Mr. Girgenti, the Cranye Girgenti Testamentary Trust, Gary Rubin, The Harvey Sandler Revocable Trust, a trust of which Mr. Rubin is a co-trustee, Ms. Zannes and Dr. Joyce consented to an amendment of the terms of the outstanding warrants that they own.”
bioAffinity Technologies, Inc. entered into Asset Purchase Agreement with Village Oaks Pathology Services, P.A. and Dr. Roby P. Joyce, M.D. valued at $3,500,000 (effective 2023-09-18).
“On September 18, 2023, bioAffinity Technologies, Inc.‘s (the “Company”) wholly-owned subsidiary, Precision Pathology Laboratory Services LLC (“PPLS”), consummated the acquisition (the “Acquisition”) of a clinical anatomic and clinical pathology laboratory and related services business in San Antonio, Texas (the “Laboratory Assets”) pursuant to the terms of an Asset Purchase Agreement (the “Asset Purchase Agreement”) dated September 18, 2023”
Xavier Reveles was appointed as Chief Operating Officer at bioAffinity Technologies, Inc..
“Xavier Reveles, age 54, who has served as the Company’s Vice President of Operations as an employee at will since September 2022, was appointed to serve as the Company’s Chief Operating Officer on September 18, 2023, contingent upon and effective as of the consummation of the Acquisition.”
Roby P. Joyce was appointed as Director at bioAffinity Technologies, Inc..
“Roby P. Joyce, MD, age 75, was appointed to serve on the Company’s Board of Directors on September 18, 2023, contingent upon and effective as of the consummation of the Acquisition.”
bioAffinity Technologies, Inc. reported second quarter of 2023; three and six months ended June 30, 2023 results: revenue $20,000, net income $1.7 million, EPS $0.20 per share.
“Revenue for the second quarter of 2023 was $20,000, compared with $1,000 for the prior-year period.”
bioAffinity Technologies, Inc.: Increased authorized shares of Common Stock from 14,285,715 to 25,000,000 (effective 2023-06-07).
“to increase the number of shares of Common Stock authorized for issuance under the Certificate of Incorporation from 14,285,715 shares to 25,000,000 shares”
bioAffinity Technologies, Inc. shareholders approved Amendment to Certificate of Incorporation to increase authorized shares from 14,285,715 to 25,000,000 at the 2023-06-06 meeting.
“the Company’s stockholders voted at the Annual Meeting to approve an amendment to the Company’s Amended and Restated Certificate of Incorporation (the “ Certificate of Incorporation ”) to increase the number of shares of Common Stock authorized for issuance under the Certificate of Incorporation from 14,285,715 shares to 25,000,000 shares”
bioAffinity Technologies, Inc. shareholders approved Amendment to the bioAffinity Technologies, Inc. 2014 Equity Incentive Plan to increase shares reserved from 1,142,857 to 2,000,000 at the 2023-06-06 meeting.
“Proposal No. 2: Amendment to the bioAffinity Technologies, Inc. 2014 Equity Incentive Plan The stockholders approved the amendment to the Company’s Incentive Plan, resulting in the Amended and Restated Incentive Plan becoming effective on June 6, 2023, as discussed in”
bioAffinity Technologies, Inc. shareholders approved Election of seven directors to serve on the Board until the next Annual Meeting at the 2023-06-06 meeting.
“Proposal No. 1: Election of Directors . The stockholders elected each of the seven director nominees to serve on the Board until the 2024 Annual Meeting of Stockholders and until such director’s successor has been duly elected and qualified. The results of the vote taken were as follows: Nominee Votes For Votes Against Abstentions Broker Non-Votes Maria Zannes 4,812,018 16,564 81,181 1,523,856 Steven Girgenti 4,803,325 25,401 81,037 1,523,856 Robert Anderson 4,794,664 32,430 82,669 1,523,856 Stuart Diamond 4,803,266 25,260 81,237 1,523,856 Peter Knight 4,792,806 34,088 82,869 1,523,856 Mohsin Meghji 4,806,317 20,577 82,869 1,523,856 Gary Rubin 4,804,751 22,137 82,875 1,430,549”
bioAffinity Technologies, Inc. reported the three months ended March 31, 2023 results: revenue $1,000, net income $1.5 million, EPS $0.18 per share.
“Revenue for the first quarter of 2023 was $1,000, compared with no revenue for the prior-year period. Revenue is currently generated exclusively from royalties from the Company’s licensee, Precision Pathology Services, from sales of CyPath ® Lung as a laboratory developed test. Research and development expenses were $370,000 for the first quarter of 2023, compared with $280,000 for the comparable period in 2022. The increase was primarily due to higher compensation costs from adding research personnel and higher R&D equipment costs. Clinical development expenses were $20,000 for the first quarter of 2023, compared with $53,000 for the first quarter of 2022. The decline was primarily attributed to lower professional fees related to clinical strategy evaluation as the Company prepares to launch the CyPath ® Lung pivotal trial. Selling, general and administrative expenses were $1.2 million for the first quarter of 2023, compared with $395,000 for the comparable period in 2022. The increas”
Michael Dougherty was appointed as Vice President and Chief Financial Officer at bioAffinity Technologies, Inc..
“Effective May 1, 2023, the Company appointed Michael Dougherty (age 44) to serve as the Company’s new Vice President and Chief Financial Officer (principal financial officer and principal accounting officer).”
Michael Edwards resigned as Chief Financial Officer at bioAffinity Technologies, Inc..
“Effective May 1, 2023, Michael Edwards, the Company’s Chief Financial Officer (principal financial officer and principal accounting officer), resigned.”
bioAffinity Technologies, Inc. reported the three and 12 months ended December 31, 2022 results: revenue approximately $2,500, net income Net loss for the fourth quarter of 2022 was $1.7 million.
“Revenue for the fourth quarter of 2022 was approximately $2,500, compared with no revenue for the prior-year period.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.